In an exciting development, the European Medicines Agency (EMA) alongside the Heads of Medicines Agencies (HMA) has introduced two groundbreaking public electronic catalogues aimed at revolutionizing access to real-world data (RWD). This initiative promises to reshape the landscape of medical research by enhancing data discoverability and transparency.
The first catalogue, known as the Catalogue of Real-World Data Sources, serves as a unified replacement for the ENCePP Resources Database. It acts as a centralized repository, consolidating a diverse array of real-world data sources. This consolidation streamlines the process for regulators, researchers, and pharmaceutical companies, enabling them to efficiently pinpoint the most relevant data sources for their specific research inquiries.
Simultaneously, the Catalogue of Real-World Data Studies marks an evolution from the EU PAS Register®. This expanded catalogue not only replaces its predecessor but also broadens its scope, encompassing a wider range of non-interventional post-authorisation studies and other research derived from real-world data. By elevating the transparency surrounding these studies, it fosters greater confidence in the integrity of research outcomes.
The primary objectives of these catalogues are threefold. Firstly, they seek to promote transparency within the realm of medical research, offering stakeholders unprecedented access to a wealth of real-world data sources and studies. Secondly, by encouraging adherence to best practices, they aim to uphold standards of quality and reliability in research methodologies. Lastly, by centralizing and standardizing access to real-world data, they endeavor to foster trust and confidence in the utilization of such data for scientific inquiry.
Overall, the introduction of these catalogues represents a significant step forward in the quest to leverage real-world data effectively in medical research. By providing a comprehensive and accessible repository of data sources and studies, EMA and HMA aim to facilitate more robust and reliable research outcomes, ultimately benefiting patients, regulators, and the pharmaceutical industry alike.1
You can access the RWD Catalogues website here.
References
- Homepage | HMA-EMA Catalogues of real-world data sources and studies. (n.d.). https://catalogues.ema.europa.eu/
Disclaimers
- The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
